Peer-Reviewed Paper Confirms Cavadex Drives Plummeting Coronary Artery Calcium Scores : Reversing the Irreversible
ROBINA AND QUEENSLAND, AUSTRALIA / ACCESS Newswire / January 21, 2026 / Today marks one of the most profound moments in the history of cardiovascular medicine.
A newly published, peer-reviewed multi-center retrospective case series has delivered irrefutable evidence that high-viscosity 2-Hydroxypropyl-β-cyclodextrin (Cavadex) can reverse established coronary artery calcification, a biological outcome long considered impossible.
Published Paper:
Longitudinal Retrospective Analysis of High-Viscosity 2-Hydroxypropyl-β-Cyclodextrin (Cavadex) in the Regression of Atherosclerotic Cardiovascular Disease: A Multi-Center Observational Case Series
Authors: Kyle Hodgetts (Cholrem Pty Ltd), James Roberts, MD
Journal: Cardiology Research and Cardiovascular Medicine (Gavin Publishers)
For more than 30 years, the cardiology world has operated under an unbreakable rule:
Once coronary artery calcium (CAC) appears on a CT scan, it never goes down.
It only increases - year after year, relentlessly - at typical annualized rates of 14-25% (often 20-30% in high-risk patients). Spontaneous, clinically significant regression is virtually unheard of in the scientific literature. Even the most powerful lipid-lowering drugs - high-intensity statins, PCSK9 inhibitors, ezetimibe combinations - do not reverse CAC scores. At best, they slow the rise; at worst, they accelerate densification and push scores higher.
That era is over.
In this real-world evidence cohort, patients using the proprietary high-viscosity rectal formulation of Cavadex achieved dramatic, objective plummeting of CAC scores:
Absolute reductions of up to **320 points** within approximately 12 months
One patient reversed a consistent **+27-28% annual progression** to **-10.5% regression** - a nearly 40-percentage-point swing in disease trajectory
Net regression magnitudes that dwarf expected progression (e.g., -865 units versus a projected +545-unit increase)
Rapid structural reversal in select cases, including a **70-point drop** in just **9 weeks**
These are not subtle statistical blips. These are biological reversals of calcified plaque burden, the very hallmark of advanced atherosclerosis long thought to be permanent scar tissue.
"This is the holy grail we have been searching for," said lead author Kyle Hodgetts. "We are no longer talking about slowing disease or stabilizing vulnerable plaques. We are witnessing rapid active removal of decades of accumulated calcification, something no therapy in the history of cardiology has reliably achieved."
Why This Changes CVD Treatment Forever
Coronary artery calcium is the single most powerful non-invasive predictor of heart attack, stroke, and cardiovascular death. A therapy capable of driving CAC scores downward fundamentally alters the treatment landscape:
For the first time, "end-stage" patients with refractory angina, diffuse multivessel disease unsuitable for stenting or bypass, or statin intolerance may have a real disease-modifying option.
The potential to prevent millions of major adverse cardiovascular events worldwide, extending healthy lifespans and slashing the global burden of the planet's #1 killer (over 19 million deaths annually).
A shift from the decades-old paradigm of "manage progression" to the new reality of "reverse the disease."
The mechanism: direct solubilization of sub-endothelial cholesterol crystals, deactivation of NLRP3-driven inflammation, and enhanced cholesterol efflux from plaque macrophages - aligns perfectly with the observed CAC regression and offers a completely novel pathway beyond LDL-receptor modulation.
The published data is consistent and profound.
Cardiology textbooks will need to be rewritten. The wait for a true reversal therapy in atherosclerosis is over.
Media & Professional Inquiries:
Kyle Hodgetts
Cholrem Pty Ltd
Email: admin@cholrem.com
About Cholrem Pty Ltd
Cholrem is an Australian biotechnology company established in 2018, dedicated to developing and validating transformative therapies that target the root causes of atherosclerotic cardiovascular disease.
SOURCE: Cholrem Pty Ltd
View the original press release on ACCESS Newswire